fluorobenzenes has been researched along with Liver Steatosis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Perrone, T | 1 |
| Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR | 1 |
| Aguila, MB; Fraulob, JC; Mandarim-de-Lacerda, CA; Souza-Mello, V | 1 |
| Itoh, Y; Jo, M; Kagawa, K; Kimura, H; Minami, M; Mitsumoto, Y; Mitsuyoshi, H; Nakajima, T; Nishikawa, T; Nishimura, T; Okada, Y; Okanoue, T; Tochiki, N; Yamaguchi, K; Yasui, K | 1 |
| Antonopoulos, S; Giannoulis, G; Kokkoris, S; Mikros, S; Mylonopoulou, M | 1 |
1 trial(s) available for fluorobenzenes and Liver Steatosis
| Article | Year |
|---|---|
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
Topics: Adipokines; Aged; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fatty Liver; Female; Fluorobenzenes; Glucose Clamp Technique; Glyburide; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin; Intra-Abdominal Fat; Italy; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrimidines; Rosuvastatin Calcium; Subcutaneous Fat; Sulfonamides; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography | 2013 |
4 other study(ies) available for fluorobenzenes and Liver Steatosis
| Article | Year |
|---|---|
Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Dyslipidemias; Fatty Liver; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Thiazolidinediones | 2014 |
Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet.
Topics: Adipokines; Adipose Tissue; Adiposity; Animals; Blood Glucose; Body Composition; Diet, High-Fat; Fatty Liver; Fluorobenzenes; Homeostasis; Insulin Resistance; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Pyrimidines; Resistin; Rosiglitazone; Rosuvastatin Calcium; Sterol Regulatory Element Binding Protein 1; Sulfonamides; Thiazolidinediones; Triglycerides | 2012 |
Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Acyl-CoA Oxidase; Alanine Transaminase; Animals; Azo Compounds; Carnitine O-Palmitoyltransferase; Catalase; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; DNA Primers; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Nonesterified; Fatty Liver; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Liver; Male; Non-alcoholic Fatty Liver Disease; Pyrimidines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides | 2013 |
Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.
Topics: Fatty Liver; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2006 |